1st Advances in Rare Bone Diseases Conference

第一届罕见骨病会议进展

• 批准号: 7541120
• 负责人: J. Edward PUZAS
• 金额: $ 3.72万
• 依托单位: UNIVERSITY OF ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-08-15 至 2009-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7541120
• 关键词: Affect; Anthropology; Applications Grants; Area; Arthritis; Arts; Authorization documentation; Biology; Biomedical Research; Bone Diseases; Cellular biology; Clinical; Clinical Research; Communities; Discipline; Disease; Drug Industry; Endocrinology; Exercise Physiology; Faculty; Gastroenterology; Genetic; Immunology; Institutes; International; Medical; Molecular Biology; Musculoskeletal; Nephrology; Orphan Disease; Orthopedics; Patients; Radiology Specialty; Rare Diseases; Research; Research Personnel; Rheumatology; Science; Scientist; Series; Skeleton; Technology; Therapeutic Human Experimentation; United States Food and Drug Administration; United States National Institutes of Health; Work; biomechanical engineering; bone; day; forging; interest; lectures; nanobiology; nutrition; programs; skin disorder; symposium

DESCRIPTION (provided by applicant): This request for R13 support will provide, in part, the means to hold a scientific and patient-interactive conference on rare bone diseases. It will be entitled "1st Advances in Rare Bone Diseases, (ARBD-1)" and will occur in Bethesda on the NIH Campus on 23- 24 October 2008. The objectives of the conference are (1) to examine the latest advances in basic, translational, and clinical research relating to a series of genetic bone diseases (2) to understand how recent advances in science may be applied to the areas of bone biology and clinical osteology (3) to allow selected trainees and junior faculty to present their relevant work to an audience of experts in the field, (4) to have an interested lay audience interact with scientific and medical experts in these bone diseases, and the pharmaceutical industry involved in bone and orphan diseases and (5) to forge new areas of understanding and need for research and therapeutics. Invited experts and attendees will represent diverse disciplines that include genetics, molecular biology, nanobiology, endocrinology, rheumatology, nephrology, gastroenterology, nutrition, exercise physiology, orthopedics, radiology, anthropology, immunology, cell biology, and biomechanical engineering, among others. The conference co-directors, and sixteen established, international bone investigators serving as the Program Committee have developed a 2-day scientific program that includes overarching plenary lectures, directed state of the art presentations, invited lectures from the Food and Drug Administration, the pharmaceutical industry involved in orphan diseases represented by rare bone diseases, and Hot Topic discussions for seven specific disease entities. The National Institute for Arthritis, Musculoskeletal and Skin Diseases, along with the Office of Rare Diseases, has endorsed this application and granted permission for its submission. This request for R13 support will provide, in part, the means to hold a scientific and patient-interactive conference on rare bone diseases. It will be entitled "1st Advances in Rare Bone Diseases, (ARBD-1)" and will occur in Bethesda on the NIH Campus on 23- 24 October 2008. The key objectives of the conference are to provide the latest research and clinical information on rare diseases affecting the skeleton and to extend and further develop partnerships between the research community and lay organizations dedicated to serving patients with these diseases. Both the FDA and corporate scientists will participate in this exchange. Additionally, this conference will facilitate transfer of the latest technology from the biomedical research community to investigators working in the rare bone disease field.

描述（由申请人提供）：R13 支持请求将部分提供举办有关罕见骨病的科学和患者互动会议的手段。会议的标题是“罕见骨疾病第一进展 (ARBD-1)”，并将于 2008 年 10 月 23 日至 24 日在 NIH 校区的贝塞斯达举行。会议的目标是 (1) 审查基础骨疾病的最新进展。与一系列遗传性骨疾病相关的转化和临床研究（2），以了解如何将科学的最新进展应用于骨生物学和临床骨学领域（3），以允许选定的学员和初级人员教师向该领域的专家观众展示他们的相关工作，(4) 让感兴趣的非专业观众与这些骨骼疾病以及涉及骨骼和孤儿疾病的制药行业的科学和医学专家互动，(5)形成新的理解领域以及研究和治疗的需求。受邀专家和与会者将代表不同学科，包括遗传学、分子生物学、纳米生物学、内分泌学、风湿病学、肾病学、胃肠病学、营养学、运动生理学、骨科、放射学、人类学、免疫学、细胞生物学和生物力学工程等。会议联合主席和作为计划委员会的 16 名国际骨科研究人员制定了为期 2 天的科学计划，其中包括总体性全体会议讲座、指导的最新技术演示、美国食品和药物管理局 (FDA) 的邀请讲座、制药以罕见骨病为代表的孤儿病行业，以及七种特定疾病实体的热点话题讨论。国家关节炎、肌肉骨骼和皮肤疾病研究所以及罕见疾病办公室已批准该申请并批准其提交。 R13 支持请求将在一定程度上提供召开有关罕见骨病的科学和患者互动会议的手段。会议主题为“罕见骨病第一进展 (ARBD-1)”，将于 2008 年 10 月 23 日至 24 日在 NIH 校区贝塞斯达举行。会议的主要目标是提供有关罕见骨病的最新研究和临床信息。影响骨骼的罕见疾病，并扩大和进一步发展研究界和致力于为患有这些疾病的患者提供服务的非专业组织之间的伙伴关系。 FDA和企业科学家都将参加这次交流。此外，本次会议将促进生物医学研究界的最新技术向罕见骨病领域的研究人员转移。